Topics | Cellgenetherapyreview.com

Optimizing seed train processes
Monday, June 02, 2025
As the CGT space grows, making therapies available to more patients will require an all-encompassing approach to improving efficiency to lower manufacturing costs. New seed train technologies can not only improve viral vector manufacturing ... read more
Precision logistics for complex therapies
Wednesday, May 28, 2025
Patient-specific therapies come with unique logistics that bring added complexity and risk to supply chains. Manufacturing these therapies will continue to require robust supply chain management, stringent quality control and specialized ... read more
Overcoming CGT starting material challenges
Wednesday, May 21, 2025
Much of the focus for making CGTs accessible and commercially viable has looked downstream at manufacturing, logistics, geography, centralization, and even intellectual property. However, the vast majority of ex vivo advanced therapies ... read more
Shooting for immune
Tuesday, May 13, 2025
While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift cell therapies to new ... read more
Above the noise: CGT developers focus on access to better treatments amid immunology boom
Monday, May 05, 2025
The urgency of unmet need has not evaded the CGT sector, which has executed a ‘strategic pivot’ into autoimmune disease. Developers with B-cell targeting therapies originally designed to detect and kill cancer cells have recognized the ... read more
From bispecifics and ADCs to better reagents
Wednesday, April 30, 2025
Advances have allowed for the creation of bispecific, ‘Fc-silenced,’ and other specialized antibody reagents tailored to specific research needs. These engineered antibodies are deepening our understanding of complex biological systems and ... read more
Advancing AAV production
Friday, March 28, 2025
As the therapeutic potential of AAV gene therapy becomes increasingly evident, so does the demand for its widespread application; however, this surge in demand poses a formidable challenge in the need for increasingly scalable and efficient... read more
Orchestrating cell and gene therapies
Tuesday, March 25, 2025
An effective orchestration platform is now essential in optimizing processes, fostering collaboration, and ensuring the safe and effective administration of CGTs. These orchestration platforms are crucial tools for approved treatment center... read more
Considerations for successful scale-up and viral vector purification
Wednesday, March 19, 2025
To scale up a process, there are several important considerations, starting with the selection of a target batch size. However, process scale-up can encounter challenges. Here, several key considerations will be discussed, and specific ... read more
A new era in cancer care
Thursday, March 13, 2025
Immunotherapy has transformed the field of oncology by harnessing the immune system’s innate ability to mount targeted attacks on cancer cells. Building on this foundation, cell and gene therapies take immunotherapy to the next level by ... read more
Is CGT ready for prime time?
Tuesday, March 11, 2025
While challenges with commercial rollouts have been attributed to clinical site readiness, reimbursement coverage and accessibility, CGT drugs to date have predominantly targeted relatively small patient populations, effectively ... read more
A standardized approach to CGT quality management
Wednesday, March 05, 2025
This article describes the thought processes involved in defining control strategies across important areas including aseptic control, material control, process control, quality control and chain of custody control. We offer examples of how... read more